Amplia gets nod for new cancer drug trial ahead of US push
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.